AngioDynamics Inc (ANGO)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $499.19M
Last updated: Nov 17, 2026 at 11:05 AM ET
AngioDynamics Inc (ANGO) Earnings: Report Dates and Results
AngioDynamics (ANGO) is expected to report earnings on Jan 4, 2027. In the quarter ended Aug 31, 2026, AngioDynamics reported EPS of -$0.04, above the -$0.10 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ANGO has an expected report date of Jan 4, 2027.
ANGO Earnings Call
The latest ANGO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, ANGO beat 25, missed 10 and matched 4. Revenue for the quarter ended Aug 31, 2026 was $80.92M, up 6.9% from $75.71M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | -$0.04 | -$0.10 | -$0.13 - -$0.10 | +60.00% | Beat | N/A | 3 | 0 up, 2 down | Oct 8, 2026 | $80.92M |
| May 31, 2026 | -$0.07 | -$0.11 | -$0.11 - -$0.07 | +36.36% | Beat | N/A | 3 | 1 up, 1 down | Jul 14, 2026 | $86.61M |
| Feb 28, 2026 | $0.02 | -$0.11 | -$0.12 - -$0.10 | +118.18% | Beat | -33.3% | 3 | 0 up, 2 down | Apr 2, 2026 | $78.42M |
| Nov 30, 2025 | -$0.15 | -$0.10 | -$0.11 - -$0.09 | -52.90% | Miss | N/A | 3 | 0 up, 2 down | Jan 6, 2026 | $79.43M |
| Aug 31, 2025 | -$0.10 | -$0.12 | -$0.14 - -$0.09 | +16.67% | Beat | N/A | 4 | 0 up, 2 down | Oct 2, 2025 | $75.71M |
| May 31, 2025 | -$0.03 | -$0.12 | -$0.17 - -$0.09 | +75.00% | Beat | N/A | 3 | 1 up, 1 down | Jul 15, 2025 | $80.16M |
| Feb 28, 2025 | $0.03 | -$0.13 | -$0.14 - -$0.11 | +123.08% | Beat | N/A | 3 | 0 up, 1 down | Apr 2, 2025 | $72.00M |
| Nov 30, 2024 | -$0.04 | -$0.11 | -$0.12 - -$0.10 | +63.64% | Beat | N/A | 3 | 0 up, 2 down | Jan 8, 2025 | $72.84M |
| Aug 31, 2024 | -$0.11 | -$0.15 | -$0.16 - -$0.13 | +26.67% | Beat | N/A | 3 | 0 up, 0 down | Oct 3, 2024 | $67.49M |
| May 31, 2024 | -$0.06 | -$0.17 | -$0.21 - -$0.12 | +64.71% | Beat | -400.0% | 3 | 0 up, 0 down | Jul 16, 2024 | $70.98M |
| Feb 29, 2024 | -$0.16 | -$0.15 | -$0.18 - -$0.11 | -6.67% | Miss | N/A | 4 | 1 up, 0 down | Apr 4, 2024 | $75.18M |
| Nov 30, 2023 | -$0.05 | -$0.07 | -$0.10 - -$0.06 | +28.57% | Beat | -600.0% | 4 | 0 up, 0 down | Jan 5, 2024 | $79.07M |
| Aug 31, 2023 | -$0.12 | -$0.13 | -$0.15 - -$0.11 | +7.69% | Beat | N/A | 4 | 0 up, 0 down | Oct 4, 2023 | $78.68M |
| May 31, 2023 | $0.02 | $0.02 | $0.01 - $0.03 | 0.00% | In line | +100.0% | 4 | 0 up, 0 down | Jul 12, 2023 | $91.07M |
| Feb 28, 2023 | -$0.03 | -$0.01 | -$0.02 - $0.00 | -200.00% | Miss | -200.0% | 4 | 0 up, 0 down | Mar 30, 2023 | $80.71M |
| Nov 30, 2022 | $0.01 | -$0.01 | -$0.02 - $0.00 | +200.00% | Beat | N/A | 4 | 0 up, 0 down | Jan 5, 2023 | $85.43M |
| Aug 31, 2022 | -$0.06 | -$0.02 | -$0.03 - -$0.01 | -200.00% | Miss | N/A | 4 | 0 up, 0 down | Oct 6, 2022 | $81.54M |
| May 31, 2022 | $0.01 | $0.01 | $0.00 - $0.01 | 0.00% | In line | N/A | 4 | 0 up, 0 down | Jul 12, 2022 | $87.00M |
| Feb 28, 2022 | $0.03 | -$0.01 | -$0.03 - $0.00 | +400.00% | Beat | +50.0% | 4 | 0 up, 0 down | Apr 7, 2022 | $73.97M |
| Nov 30, 2021 | -$0.02 | $0.01 | $0.00 - $0.01 | -300.00% | Miss | -300.0% | 4 | 0 up, 0 down | Jan 6, 2022 | $78.28M |
| Aug 31, 2021 | -$0.02 | -$0.04 | -$0.06 - -$0.03 | +50.00% | Beat | -200.0% | 4 | N/A | Sep 30, 2021 | $76.97M |
| May 31, 2021 | -$0.51 | $0.00 | -$0.01 - $0.00 | N/A | N/A | N/A | 3 | N/A | Jul 13, 2021 | $76.84M |
| Feb 28, 2021 | $0.02 | -$0.02 | -$0.04 - -$0.01 | +200.00% | Beat | +100.0% | 3 | N/A | Mar 30, 2021 | $71.18M |
| Nov 30, 2020 | $0.01 | -$0.02 | -$0.03 - -$0.01 | +150.00% | Beat | -83.3% | 3 | N/A | Jan 7, 2021 | $72.77M |
| Aug 31, 2020 | $0.02 | -$0.07 | -$0.08 - -$0.05 | +128.57% | Beat | -75.0% | 3 | N/A | Sep 29, 2020 | $70.22M |
| May 31, 2020 | -$0.06 | -$0.06 | -$0.09 - $0.00 | 0.00% | In line | -124.0% | 3 | N/A | Jul 16, 2020 | $58.33M |
| Feb 29, 2020 | $0.01 | -$0.03 | -$0.03 - -$0.03 | +133.33% | Beat | -94.7% | 3 | N/A | Apr 7, 2020 | $69.78M |
| Nov 30, 2019 | $0.06 | $0.02 | $0.01 - $0.04 | +200.00% | Beat | -72.7% | 3 | N/A | Jan 7, 2020 | $70.00M |
| Aug 31, 2019 | $0.08 | $0.04 | $0.04 - $0.05 | +100.00% | Beat | -50.0% | 4 | N/A | Oct 3, 2019 | $66.04M |
| May 31, 2019 | $0.25 | $0.26 | $0.25 - $0.26 | -3.85% | Miss | +25.0% | 4 | N/A | Jul 10, 2019 | $71.18M |
| Feb 28, 2019 | $0.19 | $0.22 | $0.20 - $0.22 | -13.64% | Miss | -24.0% | 4 | N/A | Apr 2, 2019 | $65.52M |
| Nov 30, 2018 | $0.22 | $0.21 | $0.20 - $0.22 | +4.76% | Beat | +37.5% | 4 | N/A | Jan 4, 2019 | $69.98M |
| Aug 31, 2018 | $0.16 | $0.18 | $0.16 - $0.19 | -11.11% | Miss | +33.3% | 4 | N/A | Sep 27, 2018 | $63.94M |
| May 31, 2018 | $0.20 | $0.21 | $0.20 - $0.21 | -4.76% | Miss | +5.3% | 4 | N/A | Jul 11, 2018 | $5.69M |
| Feb 28, 2018 | $0.25 | $0.19 | $0.17 - $0.20 | +31.58% | Beat | +31.6% | 5 | N/A | Mar 29, 2018 | $83.85M |
| Nov 30, 2017 | $0.16 | $0.16 | $0.15 - $0.17 | 0.00% | In line | -15.8% | 5 | N/A | Jan 4, 2018 | $86.71M |
| Aug 31, 2017 | $0.12 | $0.16 | $0.14 - $0.18 | -25.00% | Miss | -29.4% | 5 | N/A | Sep 28, 2017 | $85.41M |
| May 31, 2017 | $0.19 | $0.16 | $0.15 - $0.18 | +18.75% | Beat | 0.0% | 5 | N/A | Jul 18, 2017 | $7.06M |
| Feb 28, 2017 | $0.19 | $0.15 | N/A | +26.67% | Beat | +26.7% | N/A | N/A | Mar 30, 2017 | $85.60M |
| Nov 30, 2016 | $0.19 | $0.16 | N/A | +18.75% | Beat | +35.7% | N/A | N/A | Jan 6, 2017 | $89.03M |
Annual EPS
EPS for the fiscal year ended May 31, 2026 was -$0.30, after -$0.15 the year before. It was $0.74 for the year ended May 31, 2017, the oldest of the 9 fiscal years below with reported EPS.
| Fiscal year ended | EPS | Change |
|---|---|---|
| May 31, 2026 | -$0.30 | N/A |
| May 31, 2025 | -$0.15 | N/A |
| May 31, 2024 | -$0.39 | N/A |
| May 31, 2023 | -$0.06 | N/A |
| May 31, 2022 | Not reported | N/A |
| May 31, 2021 | -$0.46 | -605.9% |
| May 31, 2020 | $0.09 | -89.0% |
| May 31, 2019 | $0.82 | +12.3% |
| May 31, 2018 | $0.73 | N/A |
| May 31, 2017 | $0.74 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,700 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,687 | 6 | |
| 2026Q2 | Jun 30, 2026 | 5,573 | 6 | |
| 2026Q1 | Mar 31, 2026 | 2,878 | 6 | |
| 2025Q4 | Dec 31, 2025 | 6,493 | 6 | |
| 2025Q3 | Sep 30, 2025 | 5,568 | 6 | |
| 2025Q2 | Jun 30, 2025 | 7,260 | 6 | |
| 2025Q1 | Mar 31, 2025 | 6,284 | 6 | |
| 2024Q4 | Dec 31, 2024 | 7,053 | 7 |
2026Q3 Earnings Call
Opening remarks
James Clemmer President & Chief Executive Officer Thank you, operator. Good morning, everyone, and thank you for joining us for AngioDynamics' Fiscal 2026 Third Quarter Earnings Call. Joining me on today's call is Steve Trowbridge, AngioDynamics' Executive Vice President and Chief Financial Officer. Our third quarter was strong across the board, and I am proud of how our team continues to execute. We maintained our trend of driving top line growth, led by impressive growth in our Med Tech segment. Beyond the top line, we continued to deliver strong profitability by expanding our adjusted EBITDA. Our performance continues to show that our strategy to drive profitable growth in our high-margin, large Med Tech markets is working. Based on that, we are once again raising our full year guidance for net sales and adjusted EBITDA. That is our third consecutive quarter of raised guidance, and Steve will touch upon the details shortly. I am very proud of the resilience we have built into the business. We've developed this company around cardiovascular and oncology markets with three product portfolios that we are really excited about. Along the way, we've had to work through a manufacturing transition, deal with tariffs and manage through a lot of macro uncertainty. None of that has slowed us down. That is because we have great people who know how to get the job done and the results we are putting up are not because one thing went right; it is years of work coming together. Within our Med Tech business, Auryon continued its strong momentum with the nineteenth consecutive quarter of double-digit year-over-year growth, which is a track record we are very proud of. We have consistently driven revenue growth by leveraging our superior technology to take share and our push into the hospital market keeps paying off, driving both top line growth and better economics. And it is not just about taking share. With our AMBITION BTK study, we are not only winning in the current market, we are working to make the market larger. Internationally, we are seeing continued traction following our CE Mark approval. Turning to our Mechanical Thrombectomy business. We loved what we saw this quarter. Our combined portfolio of AlphaVac and AngioVac grew approximately 18% over the prior year, demonstrating the superior clinical performance of this portfolio. AlphaVac in particular had an outstanding quarter, delivering strong year-over-year growth and driving the largest sequential revenue increase we have seen since its launch. New accounts are coming on, more hospitals are bringing us through the VAC process and into inventory. And utilization within existing accounts keeps increasing. The physician feedback on this product is consistently strong.
Frequently Asked Questions About ANGO
When is AngioDynamics's next earnings date?
AngioDynamics's next earnings report is expected for Jan 4, 2027.
Did ANGO beat earnings estimates last quarter?
Yes. AngioDynamics reported EPS of -$0.04 for the quarter ended Aug 31, 2026, above the -$0.10 estimate, a 60.00% surprise.
What EPS do analysts expect from ANGO next quarter?
The consensus EPS estimate for AngioDynamics for the quarter ending Nov 30, 2026 is -$0.07 from 3 analysts, with estimates from -$0.11 to -$0.02.
How often does ANGO beat earnings estimates?
AngioDynamics beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +55.00%.
ANGO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts